PKM2 inhibitor (compound 3k): A Selective Cancer Cell Metabolism Inhibitor

Executive Summary: PKM2 inhibitor (compound 3k) is a potent, selective inhibitor of pyruvate kinase M2 (PKM2), crucial in the regulation of glycolytic flux in tumor cells and immune cell metabolic reprogramming (Wu et al., 2025). This compound exhibits an IC₅₀ of 2.95 μM against PKM2 and demonstrates nanomolar antiproliferative effects in high-PKM2-expressing cancer cell lines, including HCT116, Hela, and H1299. In vivo, the inhibitor significantly reduces ovarian tumor growth in BALB/c nude mice without notable toxicity. Mechanistic studies confirm PKM2 inhibition results in disrupted aerobic glycolysis, affecting both cancer cell viability and pro-inflammatory macrophage polarization. PKM2 inhibitor (compound 3k) is supplied by APExBIO as SKU B8217 and is strictly indicated for research use only.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a rate-limiting enzyme in the glycolytic pathway and is preferentially expressed in proliferating tumor cells and activated immune cells (Wu et al., 2025). Cancer cells rely on aerobic glycolysis (the Warburg effect) for rapid energy generation and anabolic precursor supply. PKM2 modulates metabolic flux by toggling between its tetrameric (active) and dimeric/monomeric (inactive) forms, which in turn influences the balance between glycolysis and oxidative phosphorylation. In immune cells, especially macrophages, PKM2 regulates polarization and inflammatory responses through metabolic reprogramming. Targeting PKM2 with selective inhibitors disrupts these pathological metabolic programs, representing a rational strategy for cancer and immunometabolic disease intervention (Wu et al., 2025).

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) binds to the allosteric site of PKM2, stabilizing its inactive forms and reducing pyruvate formation from phosphoenolpyruvate. This inhibition blocks conversion of glucose to lactate, thereby disrupting the glycolytic pathway that fuels tumor proliferation and survival. In immune cells, PKM2 inhibition alters macrophage polarization from pro-inflammatory (M1) to anti-inflammatory (M2) states by modulating metabolic flux. The compound’s selectivity for PKM2 over PKM1 and other isoforms reduces off-target effects, with IC₅₀ values of 2.95 μM for PKM2, and nanomolar antiproliferative potency in high-PKM2-expressing cell lines. Additionally, PKM2 inhibition can trigger autophagic cell death in malignant cells (Wu et al., 2025).

Evidence & Benchmarks

• PKM2 inhibitor (compound 3k) inhibits recombinant PKM2 with an IC₅₀ value of 2.95 μM (in vitro enzymatic assay at 25°C, pH 7.4) (APExBIO).
• Demonstrates antiproliferative activity in HCT116 (0.18 μM), Hela (0.29 μM), and H1299 (1.56 μM) cancer cell lines (72 h exposure, standard RPMI media, 37°C) (Wu et al., 2025).
• Exhibits higher cytotoxicity towards cancer cells than normal human BEAS-2B lung epithelial cells (IC₅₀ > 10 μM, 72 h exposure) (APExBIO).
• Oral administration (5 mg/kg, every two days for 31 days) in BALB/c nude mice bearing SK-OV-3 ovarian xenografts led to significant tumor volume and weight reduction, with no major organ toxicity observed (histopathology, body weight monitoring) (Wu et al., 2025).
• In severe acute pancreatitis (SAP) mouse models, PKM2 inhibition with compound 3k reversed the metabolic effects of USP7 knockdown on macrophage polarization (in vivo, 6 h post-induction, 30–34°C) (Wu et al., 2025).

For a deeper exploration of how PKM2 inhibition interfaces with immune cell modulation, see this article, which details immunometabolic reprogramming strategies beyond the cancer context. This article extends those findings by providing updated in vivo efficacy data and clinical translation considerations.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is primarily used as a research tool for dissecting PKM2-driven metabolic pathways in cancer and immune cells. It allows for precise modulation of glycolytic flux, enabling studies on cancer metabolism, cell viability, and immune cell phenotype. The compound's selectivity supports experiments requiring distinction between PKM2 and other pyruvate kinase isoforms. In vivo, it models tumor regression and immune modulation, particularly in ovarian and other high-PKM2-expressing cancers. For practical laboratory applications and troubleshooting, see the scenario-driven workflows in this guide; this current article updates those protocols with new selectivity and safety benchmarks.

Common Pitfalls or Misconceptions

• Not effective in PKM2-low or PKM1-dominant cells: The inhibitor is selective for PKM2 and demonstrates reduced efficacy in cells with low PKM2 expression.
• Not a universal antiproliferative agent: Activity is limited to specific tumor types with high glycolytic flux and PKM2 expression.
• Does not induce direct cytotoxicity in normal epithelial cells: Demonstrates lower toxicity in BEAS-2B and other non-cancerous lines.
• Not recommended for long-term solution storage: Solutions in DMSO should be freshly prepared; compound degrades over time at room temperature or in aqueous buffers.
• Not indicated for therapeutic use in humans: For research use only, not for diagnostic or clinical application.

For additional insight into enhancing assay reliability and selectivity with PKM2 inhibitor (compound 3k), reference this workflow guide, which this article builds upon by clarifying limitations and storage considerations.

Workflow Integration & Parameters

PKM2 inhibitor (compound 3k) is supplied as a solid (SKU B8217) with a molecular weight of 345.48 (C₁₈H₁₉NO₂S₂). It is soluble at ≥34.5 mg/mL in DMSO with gentle warming. The compound is insoluble in ethanol and water. Recommended storage is at -20°C; long-term solution storage is discouraged. For in vitro assays, typical working concentrations range from 0.1–10 μM in cell culture media. In vivo, published studies use oral dosing at 5 mg/kg every 48 hours for up to 31 days in mouse xenograft models. Always match concentration and vehicle to the experimental system.

Conclusion & Outlook

PKM2 inhibitor (compound 3k) from APExBIO represents a validated, selective tool for interrupting cancer cell metabolism and studying immunometabolic pathways. Its use enables mechanistic dissection of glycolytic flux, cancer cell viability, and macrophage polarization in both in vitro and in vivo models. Ongoing research explores clinical translation and the potential for combination therapies targeting metabolic vulnerabilities. For product details and ordering, visit the PKM2 inhibitor (compound 3k) product page.